Abstract
Background Infections are one of the most common causes of neonatal mortality, and maternal colonization has been associated with neonatal infection. Data on carriage of bacterial pathogens and mother-child transmission patterns in low- and middle-income countries is sparse.
Methods We sought to quantify carriage prevalence of extended-spectrum-beta-lactamase (ESBL) - producing and carbapenem-resistant Enterobacterales (CRE) among pregnant women and their neonates and to characterize risk factors for carriage in a rural area of Amhara, Ethiopia. We sampled 211 pregnant women in their third trimester and/or labor/delivery and 159 of their neonates in the first week of life.
Results We found that carriage of ESBL-producing organisms was fairly common (women: 22.3%, 95% CI: 16.8-28.5; neonates: 24.5%, 95% CI: 18.1-32.0), while carriage of CRE (women: 0.9%, 95% CI: 0.1-3.4; neonates: 2.5%, 95% CI: 0.7-6.3) was rare. Neonates whose mothers tested positive for ESBL-producing organisms were nearly twice as likely to also test positive for ESBL-producing organisms (38.7% vs. 21.1%, p-value: 0.06). Carriage of ESBL-producing organisms was also associated with woreda (district) of sample collection (Fisher exact test maternal p-value: <0.01; neonatal p-value: <0.01) and recent antibiotic use (maternal p-value: 0.55; neonatal p-value: 0.011).
Conclusions Understanding carriage patterns of potential pathogens and antibiotic susceptibility among pregnant women and newborns in this region will help to inform local, data-driven recommendations to prevent and treat neonatal infections.
Main point Carriage prevalence of ESBL-producing Enterobacterales was high among pregnant women and neonates in a rural area of Ethiopia, and neonates were more likely to test positive if their mother tested positive. This work informs prevention and treatment of neonatal infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill & Melinda Gates Foundation [INV-010382 to G.C.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Review Board (IRB) of Saint Pauls Hospital Millennium Medical college (Addis Ababa Ethiopia) gave ethical approval for this work [PM23/274] Boston Childrens Hospital (Boston United States) gave ethical approval for this work [IRB-P00028224] Harvard T.H. Chan School of Public Health (Boston United states) gave ethical approval for this work [IRB19-0991]
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified data will be made publicly available upon publication of the manuscript.
